RKDA Arcadia Biosciences, Inc.
Beverages · Nasdaq · SEC CIK 1469443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-101.9%
TTM EPS YoY9.4%
Revenue 3-yr CAGR3.5%
Net income 3-yr CAGR—
Margins
Gross margin41.1%
Operating margin-68.9%
Net margin-202.1%
FCF margin—
EBITDA margin-68.7%
Returns
ROE-260.8%
ROA-153.9%
ROIC (approx.)-142.0%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets49.0%
Debt / equity0.00x
Current ratio3.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-100.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.62M | $1.44M | $1.10M | $901,000 | $1.30M | $1.46M | $1.20M | $1.22M |
| Cost of revenue | $760,000 | $812,000 | $700,000 | $709,000 | $884,000 | $824,000 | $682,000 | $827,000 |
| Gross profit | $859,000 | $631,000 | $400,000 | $192,000 | $418,000 | $631,000 | $518,000 | $389,000 |
| R&D expense | $0 | $0 | — | $0 | $0 | $9,000 | $0 | $13,000 |
| SG&A expense | $1.70M | $1.13M | $1.18M | $1.57M | $1.57M | $2.12M | $1.74M | $2.65M |
| Operating income | -$839,000 | -$496,000 | -$779,000 | -$1.38M | -$1.15M | -$501,000 | $530,000 | -$2.28M |
| Pretax income | — | — | — | — | — | — | — | -$4.03M |
| Income tax | — | — | — | — | — | — | — | $8,000 |
| Net income | $1.75M | -$6.27M | -$4.38M | -$1.34M | $856,000 | -$4.46M | $2.60M | -$4.06M |
| EBITDA | -$839,000 | -$496,000 | -$771,000 | -$1.37M | -$1.15M | -$486,000 | $543,000 | -$2.31M |
| EPS (basic) | 0.29 | -2.09 | -2.11 | — | 0.63 | -3.26 | 1.90 | — |
| EPS (diluted) | 0.29 | -2.09 | -2.11 | — | 0.62 | -3.26 | 1.90 | — |
| Weighted avg. shares (diluted) | 6.07M | 2.99M | 2.08M | — | 1.37M | 1.37M | 1.37M | — |
| Banking | ||||||||
| Net interest income | $20,000 | $2,000 | $5,000 | -$1,000 | $7,000 | $9,000 | $207,000 | $354,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $2.84M | $4.18M | $954,000 | $259,000 | $1.12M | $1.38M | $3.16M | $4.24M |
| Short-term investments | $0 | $0 | $2.77M | $4.30M | $4.76M | $3.07M | — | $0 |
| Inventory | $973,000 | $930,000 | $840,000 | $1.21M | $1.46M | $1.49M | $1.28M | $904,000 |
| Current assets | $4.56M | $5.74M | $5.17M | $6.36M | $8.39M | $7.58M | $8.85M | $9.24M |
| PP&E, net | $0 | $0 | $0 | $8,000 | $10,000 | $12,000 | $28,000 | $41,000 |
| Intangibles | $39,000 | $39,000 | $39,000 | $39,000 | $39,000 | $39,000 | $39,000 | $39,000 |
| Total assets | $4.72M | $5.89M | $5.32M | $6.55M | $8.58M | $7.79M | $12.99M | $13.52M |
| Current liabilities | $1.27M | $1.65M | $1.36M | $2.06M | $2.29M | $1.84M | $2.22M | $2.56M |
| Total liabilities | $2.31M | $5.26M | $2.44M | $2.41M | $3.14M | $3.25M | $4.08M | $7.29M |
| Shareholders' equity | $2.40M | $633,000 | $2.88M | $4.14M | $5.44M | $4.53M | $8.90M | $6.22M |
| Shares outstanding | 5.13M | 2.18M | 2.06M | 1.37M | 1.37M | 1.37M | 1.37M | 1.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.28M | -$319,000 | -$1.10M | -$861,000 | -$257,000 | -$2.03M | -$1.59M | -$2.21M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | — | — | — | -$861,000 | -$257,000 | -$2.03M | -$1.59M | -$2.21M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $250,000 | $500,000 | $2.52M |
| Financing cash flow | -$55,000 | $3.54M | $1.79M | $0 | $1,000 | $0 | $5,000 | $0 |
| Depreciation & amortization | $0 | $0 | $8,000 | $2,000 | $2,000 | $15,000 | $13,000 | -$34,000 |
| Stock-based compensation | $14,000 | $14,000 | $15,000 | $17,000 | $53,000 | $86,000 | $78,000 | $117,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.